Sec Form 3 Filing - Harding Thomas C. @ Clovis Oncology, Inc. - 2020-12-03

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Harding Thomas C. 2. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [ CLVS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 12/03/2020 (Street) BOULDER, CO80301 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 3,210 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 73.98 ( 1 ) 01/10/2024 Common Stock 2,167 D Stock Option (right to buy) $ 78.38 ( 2 ) 02/27/2024 Common Stock 30,000 D Stock Option (right to buy) $ 79.05 ( 3 ) 03/02/2025 Common Stock 9,350 D Stock Option (right to buy) $ 85.88 ( 4 ) 07/01/2025 Common Stock 20,000 D Stock Option (right to buy) $ 22.73 ( 5 ) 08/25/2026 Common Stock 21,047 D Stock Option (right to buy) $ 59.27 ( 6 ) 03/01/2027 Common Stock 4,250 D Stock Option (right to buy) $ 58.43 ( 7 ) 03/01/2028 Common Stock 4,500 D Stock Option (right to buy) $ 3.4 ( 8 ) 10/30/2029 Common Stock 35,000 D Restricted Stock Units ( 13 ) ( 9 ) 03/01/2027 Common Stock 516 D Restricted Stock Units ( 13 ) ( 10 ) 03/01/2028 Common Stock 1,688 D Restricted Stock Units ( 13 ) ( 11 ) 02/01/2029 Common Stock 14,063 D Restricted Stock Units ( 13 ) ( 12 ) 01/31/2030 Common Stock 29,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Harding Thomas C. C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO80301 See Remarks Signatures /s/ Thomas C. Harding 12/07/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On January 10, 2014, the reporting person was granted 8,000 options. The options are fully vested and are immediately exercisable. ( 2 )On Februa ry 27, 2014, the reporting person was granted 30,000 options. The options are fully vested and are immediately exercisable. ( 3 )On March 2, 2015, the reporting person was granted 9,350 options. The options are fully vested and are immediately exercisable. ( 4 )On July 1, 2015, the reporting person was granted 20,000 options. The options are fully vested and are immediately exercisable. ( 5 )On August 25, 2016, the reporting person was granted 33,675 options. The options are fully vested and are immediately exercisable. ( 6 )On March 1, 2017, the reporting person was granted 4,250 options. The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. ( 7 )On March 1, 2018, the reporting person was granted 4,500 options. The option vested as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date. ( 8 )On October 30, 2019, the reporting person was granted 35,000 options. The option vests as to 25% of the shares on October 30, 2020, and the remainder vests in substantially equal installments over the 36 months immediately following such date. ( 9 )On March 1, 2017, the reporting person was granted 4,125 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. ( 10 )On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. ( 11 )On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. ( 12 )On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vest on January 31, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. ( 13 )Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Remarks: Senior Vice President and Chief Scientific Officer

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.